Table 3.

Initial actionability attributable to established PGx guidelines, the emerging CYP2C haplotype, and phenoconversion.

Initial actionability	No. of patients	% of Patients	% of Actionability that is NGS dependent
PGxa	2732	66	2
CYP2Cb	402	10	100
Phenoconversionc	464	11	1
Noned	516	13	1
Anye	3598	87	11

^a“PGx” indicates the patient had a potentially actionable CYP2D6 or CYP2C19 phenotype.

^b“CYP2C” indicates the patient was expected to carry the CYP2C-TG allele.

^c“Phenoconverison” indicates the patient had a reported medication resulting in CYP2D6 phenoconversion.

^d“none” indicates the patient had no potentially actionable phenotype, did not harbor the CYP2C haplotype, and did not have phenoconversion.

^e“any” indicates the patient had at least one source of actionability among PGx, novel CYP2C, and/or phenoconversion.